PCSK9: NEW VICTORY AND HORIZONS
M.O. Smolina, K.S. Benimetskaya, Yu.I. Ragino, M.I. Voevoda
Institutе of Internal and Preventive Medicine - Вranch of Federal Research Institute of Cytology and Genetics of SB RAS, 630089, Novosibirsk, Boris Bogatkov str., 175/1
Keywords: ингибиторы пропротеинконвертаза субтилизин/кексин 9 типа, PCSK9, гиперхолестеринемия, семейная гиперхолестеринемия, гипертриглицеридемия, алирокумаб, эволокумаб, inhibitors ofproprotein convertase subtilisin/kexin type 9, PCSK9, Familial Hypercholesterolemia, hypertriglyceridemia, alirocumab, evolocumab
Abstract
The review presents the latest data from the world scientific literature of clinical studies of inhibitors protoprotein convertasesubtilisin/kexin 9 type (PCSK9). The results of the most important completed clinical trials and announcements of prospective clinical trials are presented, the completion of which is expected in the near future. The place of PCSK9 inhibitors in modern recommendations of the European and Russian Cardiological Society is highlighted.The results of studies on the efficacy and safety of PCSK9 inhibitors in selected patient groups (familial hypercholesterolemia, hypertriglyceridemia) are presented. A review of the research aimed at finding new inhibition mechanisms for PCSK9, opening new horizons in the treatment of patients with dyslipidemia.
|
